Shares of Mallinckrodt MNK decreased 24% in pre-market trading after the company reported Q2 results.
Earnings per share were down 25.30% over the past year to $1.89, which beat the estimate of $1.35.
Revenue of $700,900,000 decreased by 14.87% year over year, which beat the estimate of $635,330,000.
Earnings guidance hasn't been issued by the company for now.
Mallinckrodt hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 04, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/q3neeh49
Company's 52-week high was at $6.87
Company's 52-week low was at $1.00
Price action over last quarter: down 25.17%
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.